Monitor ZEO's progress toward Nasdaq uplisting and commercialization milestones, as the partnership's value depends on ZEO executing its manufacturing and sales plan within 12-18 months. The activist stake at 38.85% adds pressure for near-term value realization.
Price Chart
Executive Summary
Pluri Inc. entered into a strategic partnership with ZEO ScientifiX, granting ZEO an exclusive license to manufacture and commercialize Pluri's regenerative medicine products in the U.S. in exchange for a 50% equity stake in ZEO (41% common stock at closing plus 4% from secondary sales, with potential milestone step-ups). Concurrently, Pluri raised $0.5 million via a private placement of 454,546 shares at $1.10 per share with warrants for an additional 454,546 shares at $1.30. The transaction was announced three days after an activist investor (Chutzpah Holdings) increased its stake to 38.85% of Pluri, suggesting the partnership may be a strategic response to activist pressure.
Key Financial Metrics
Key Facts
- Pluri and ZEO ScientifiX signed a partnership agreement effective October 26, 2026, granting ZEO an exclusive, royalty-bearing license to manufacture and commercialize Pluri's regenerative medicine products in the U.S.
- At closing, ZEO will issue Pluri common stock representing 41% of ZEO's outstanding shares, plus 50 Series D Preferred Shares; Pluri will also acquire an additional 4% from selling shareholders via secondary sale, for a total initial economic ownership of 50%.
- Pluri raised $0.5 million via a private placement of 454,546 shares at $1.10 per share, with warrants to purchase an additional 454,546 shares at $1.30 per share.
- The partnership includes milestone-based equity step-ups for Pluri: a 5% tranche at $5.50 VWAP, and warrants for 5% at $4.00 and 2.5% at $5.50.
- Royalty rates on net sales range from redacted levels (below 7%) depending on Pluri's ownership percentage in ZEO.
- An activist investor (Chutzpah Holdings) filed a Schedule 13D/A on October 27, 2026, disclosing a 38.85% stake in Pluri after acquiring 833,334 shares at $1.50 per share.
- Pluri's market cap is $17M; the $0.5M offering represents approximately 2.9% of market cap.
Financial Impact
Pluri receives 50% of ZEO's equity (41% common + 4% secondary + 5% additional) and a royalty on U.S. net sales of licensed products; Pluri raised $0.5M in a concurrent private placement.
Risk Factors
- Closing is subject to multiple conditions including IIA approval, due diligence, and independent valuations; failure to close by January 24, 2027 allows termination.
- ZEO has material weaknesses in internal controls (per its 10-K) that must be remediated within 6 months of closing.
- Pluri's $0.5M offering at $1.10 per share represents a discount to the activist's recent $1.50 purchase price.
- The partnership grants ZEO no clinical trial rights; all human studies remain with Pluri, limiting ZEO's ability to advance products independently.
- Document contains text addressed to automated readers (redaction markers, bracketed placeholders).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-114079 |
| Document: ea031025901ex10-2.htm | 0001213900-26-114079 |
| Document: ea031025901ex4-1.htm | 0001213900-26-114079 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 30, 2026 2d ago | 8-K | $1.26 | awaiting T+20 | awaiting T+20 | $1.24 (−1.20%) |
Oct 27, 2026 5d ago | SC 13D/A | $1.19 | awaiting T+20 | awaiting T+20 | $1.24 (+4.20%) |
Oct 20, 2026 12d ago | 8-K | $1.05 | awaiting T+20 | awaiting T+20 | $1.24 (−18.10%) |
Oct 16, 2026 16d ago | EFFECT | $0.9299 | awaiting T+20 | awaiting T+20 | $1.24 (−33.35%) |
Oct 6, 2026 26d ago | S-1 | $1.04 | awaiting T+20 | awaiting T+20 | $1.24 (+19.23%) |
Aug 28, 2026 9w ago | 424B5 | $1.53 $0.9700 | ▲ +36.60% | ▲ +36.86% | $1.24 (+18.95%) |
Aug 28, 2026 9w ago | 8-K | $1.53 $0.9700 | ▲ +36.60% | ▲ +36.86% | $1.24 (+18.95%) |
Aug 17, 2026 10w ago | 8-K | $1.63 $1.19 | ▼ −26.99% | ▼ −26.00% | $1.24 (−23.93%) |
Aug 17, 2026 10w ago | Press Release | $1.60 $1.17 | ▼ −26.61% | ▼ −24.63% | $1.24 (−22.50%) |
Jul 14, 2026 15w ago | 8-K | $1.75 $1.63 | ▲ +7.14% | ▲ +9.49% | $1.24 (+29.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers